生物医药行业近年来在癌症疫苗领域也获得多项进展。Moderna和默沙东联合开发的mRNA个体化癌症疫苗mRNA-4157正在多个后期临床试验中接受评估，治疗的癌症类型包括高危黑色素瘤、非小细胞肺癌、肾细胞癌、尿路上皮癌、皮肤鳞状细胞癌。它近日被行业媒 ...

1. 百时美施贵宝宣布，欧洲药品管理局人用药品委员会推荐批准其PD-1抑制剂Opdivo与CTLA-4靶向抗体Yervoy联合疗法用于不可切除或晚期肝细胞癌成人患者的一线治疗。 2. 3期CheckMate-9DW临床试验结果显示，Opdivo联合Yervoy治疗在临床与统计学上显著延长主要终点OS，中位OS为23.7个月，而活性对照药物治疗患者的中位OS为20.6个月。

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...

The drug is called ipilimumab. Before it came along there were no successful treatments for advanced melanoma and less than 3% of patients survived for five years. Now, with immunotherapy regimens ...

During a Case-Based Roundtable® event, Neeraj Agarwal, MD, and participants discussed how they might determine which ...

Top-line, phase 3 results for Bristol-Myers Squibb's humanized monoclonal antibody (mAb) ipilimumab showed a survival benefit in patients with advanced cancer—the first ever phase 3 trial to do so.

Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...

Erratum: Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial Supported in part ...

This trial is looking at adding SCIB1 or iSCIB1+ to nivolumab and ipilimumab for melanoma. It is also looking at adding SCIB1 to pembrolizumab for melanoma. It is for people whose melanoma has grown ...

Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.

In a phase 1 trial, all 9 patients with renal cell carcinoma treated with a neoantigen-targeting personalized cancer vaccine showed no recurrence at data cutoff.